Inhibition of RGMa Alleviates Symptoms in a Rat Model of Neuromyelitis Optica
Authors
Affiliations
Neuromyelitis optica (NMO) is an autoimmune disease associated with NMO immunoglobulin G (NMO-IgG), an antibody that selectively binds to the aquaporin-4. Here, we established a localized NMO model by injecting NMO-IgG into the spinal cord, and assessed the efficacy of treating its NMO-like symptoms by blocking repulsive guidance molecule-a (RGMa), an axon growth inhibitor. The model showed pathological features consistent with NMO. Systemic administration of humanized monoclonal anti-RGMa antibody delayed the onset and attenuated the severity of clinical symptoms. Further, it preserved astrocytes and reduced inflammatory-cell infiltration and axonal damage, suggesting that targeting RGMa is effective in treating NMO.
Uno H, Itokazu T, Yamashita T Commun Biol. 2025; 8(1):263.
PMID: 39972167 PMC: 11840113. DOI: 10.1038/s42003-025-07696-7.
Bai Y, Di G, Ge H, Li B, Zhang K, Zhang D Invest Ophthalmol Vis Sci. 2023; 64(12):27.
PMID: 37707834 PMC: 10506685. DOI: 10.1167/iovs.64.12.27.
Yu T, Huo L, Lei J, Sun J, Wang H Inflammation. 2022; 45(6):2223-2242.
PMID: 35789312 DOI: 10.1007/s10753-022-01686-1.
Hirata T, Itokazu T, Sasaki A, Sugihara F, Yamashita T Front Immunol. 2022; 13:870126.
PMID: 35784362 PMC: 9241446. DOI: 10.3389/fimmu.2022.870126.
Tang J, Zeng X, Yang J, Zhang L, Li H, Chen R Front Immunol. 2022; 13:766099.
PMID: 35185873 PMC: 8850277. DOI: 10.3389/fimmu.2022.766099.